Candel Therapeutics Stock Surges Over 100% - Here's Why

Benzinga12-11

On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. The ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490500868?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nDjxpCLgOwkmuNsyCdOK1g--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a19e371962c82e7dfb3607b879d698c0","is_english":true,"pubTime":"2024-12-11 22:19","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490500868","market":"us","top_or_hot":-1,"title":"Candel Therapeutics Stock Surges Over 100% - Here's Why","media":"Benzinga","content":"<div>\n<p>On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. \nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/candel-therapeutics-stock-surges-over-141944723.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Stock Surges Over 100% - Here's Why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Stock Surges Over 100% - Here's Why\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 22:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/candel-therapeutics-stock-surges-over-141944723.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. \nThe ...</p>\n\n<a href=\"https://finance.yahoo.com/news/candel-therapeutics-stock-surges-over-141944723.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861220207.SGD","symbol_name":"Blackrock FinTech A2 SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/candel-therapeutics-stock-surges-over-141944723.html","article_id":"2490500868","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nDjxpCLgOwkmuNsyCdOK1g--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a19e371962c82e7dfb3607b879d698c0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490500868","pubTimestamp":1733926784,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Wednesday, Candel Therapeutics, Inc.  announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients.The trial met its primary endpoint and demonstrated statistically significant improvement in disease-free survival in patients who received CAN-2409 plus the prodrug  combined with the standard of care compared to the standard of care alone.CAN-2409, when administered with valacyclovir, is designed to induce immunogenic cell death of tumor cells by exposing them to tumor antigens in the context of an activated tumor microenvironment.At 54 months, the CAN-2409 treatment arm observed a 14.5% relative improvement in DFS compared to the placebo control arm.In an analysis that focused on prostate-specific outcomes, CAN-2409 showed a highly significant effect on prostate cancer-free survival.The safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identified. The most c","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861220207.SGD":"Blackrock FinTech A2 SGD-H","LU0106831901.USD":"贝莱德世界金融基金A2","BK4084":"特种房地产投资信托","LENZ":"Therapeutics","BK4588":"碎股","BK4217":"自存仓储房地产信托","PSA":"公共存储公司","BK4600":"加密货币概念","LU2360107671.USD":"BGF FINTECH \"A4\" (USD) INC","BK4170":"电脑硬件、储存设备及电脑周边","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","BK4539":"次新股","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4595":"比特币概念","CADL":"Candel Therapeutics, Inc.","DFS":"发现金融","BK4166":"消费信贷","LU1861217088.USD":"贝莱德金融科技A2","BK4526":"热门中概股"},"translate_title":"Candel Therapeutics股价飙升超过100%——原因如下","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSA":1,"LENZ":1,"DFS":1,"CADL":1},"content_text":"On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. \nThe trial met its primary endpoint and demonstrated statistically significant improvement in disease-free survival in patients who received CAN-2409 plus the prodrug (valacyclovir) combined with the standard of care compared to the standard of care alone.\nCAN-2409, when administered with valacyclovir, is designed to induce immunogenic cell death of tumor cells by exposing them to tumor antigens in the context of an activated tumor microenvironment.\nKey topline results include:\n\nStatistically significant improvement in disease-free survival (DFS) for CAN-2409 plus radiation therapy (n=496) vs. radiation therapy alone (n=249) (p=0.0155; HR 0.7) in the intent-to-treat population.\nAt 54 months, the CAN-2409 treatment arm observed a 14.5% relative improvement in DFS compared to the placebo control arm.\nDFS improvement was observed in patients receiving short-term ADT and those not receiving ADT.\nIn an analysis that focused on prostate-specific outcomes, CAN-2409 showed a highly significant effect on prostate cancer-free survival.\nA significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the treatment arm compared to the placebo control arm (67.1% vs. 58.6%, respectively; p<0.0164).\nCAN-2409 induced 80.4% pathological complete responses (pCRs) in the 2-year post-treatment biopsies compared to 63.6% observed in the control arm (p=0.0015).\nThe median follow-up time for the recruited population was 50.3 months.\n\nThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identified. The most common CAN-2409-related adverse events were flu-like symptoms, fever and chills, which were generally mild to moderate in severity and self-limited.\nThe company also reported that the phase 2 clinical trial of monotherapy CAN-2409 in 190 patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance.\nThe trial showed numerical improvement in time to radical treatment and the percentage of patients achieving negative (prostate cancer-free) biopsies at 1-year post-treatment. However, these differences did not reach statistical significance.\nPrice Action: CADL stock is up 167.70% at $12.34 during the premarket session at last check Wednesday.\nRead Next:\n\nPenny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder\n\nUNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.\nGet the latest stock analysis from Benzinga?\n\nThis article Candel Therapeutics Stock Surges Over 100% - Here's Why originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490500868"}